CClinicalTrials.gg
Status unknownNCT03810157Updated Jun 25, 2019

Does LAH May Improve the Pregnancy Outcomes?

An interventional study of Laser-assisted hatching system in Pregnancy Outcomes, sponsored by Tang-Du Hospital. Status unknown at 1 site in China. Open to female participants aged 22 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-06-25.

Sponsored by Tang-Du Hospital · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2019), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
1,200
Allocation
Randomized
Ages
22 Years to 45 Years
Sex
Female
01

Study summary

A defect in the hatching stage is considered an important cause of implantation failure. Therefore, assisted hatching (AH), which involves artificial disruption of the zona pellucida, has been proposed as a method for improving the capacity of the embryo to implant. But the advantage of using laser to facilitate the hatching process of embryos in ART practice is debatable, and an optimum strategy for performing LAH remains elusive. Therefore, the aim of this study was to evaluate the effects of laser-assisted hatching(LAH) on clinical outcomes. Patients were randomly divided into control and LAH groups. The zona pellucida was thinned or drilled with a diode laser. Relevant parameters are recorded to evaluate the validity of LAH in ART.

Read the detailed description

Hatching is a very important process for successful implantation involving the breaking of the embryo out of the zona pellucida at the blastocyst stage. Inadequate hatching of the blastocyst might lead to implantation failure in ART. Currently, a variety of AH techniques have been used including zona thinning and the opening or complete removal of the zona by laser. But the advantage of using laser to facilitate the hatching process of embryos in ART practice is debatable, and an optimum strategy for performing LAH remains elusive. Therefore, the investigator aim to discuss the effectiveness of LAH in ART.

In this study, patients were randomly divided into control and LAH groups. A quarter of zona pellucida of the cleavage-stage embryo was thinned to 6.6 μm. All operation was performed in the empty region without contact to the blastomere in order to minimize the blastomere damage. The ZP of blastocyst was drilled with laser, the ZP opening 20% of its initial length. The operation was performed in the opposite region of ICM in order to minimize the damage. In the control group, embryos were transplanted without LAH. The rate of clinical pregnancy, live-birth, miscarriage, multiple gestation were evaluated. This research intends to discuss whether LAH can improve the clinical outcomes in ART, and further choice the appropriate LAH action site.

02

Conditions studied

  • Pregnancy Outcomes

Keywords

  • laser-assisted hatching (LAH)
  • zona pellucida
  • cryopreservation
  • pregnancy outcomes
03

In context

Lead sponsor

Tang-Du Hospital is the lead sponsor of 164 studies on the registry; 77 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Patients undergoing IVF/ICSI-ET cycle;
  • The zone pellucida of the cleavage-stage embryo is thicker than 8 μm.

Exclusion criteria

Exclusion Criteria:

  • Number of embryos transferred per cycle >2;
  • The transferred embryos including fresh and frozen cycle in the same cycle;
  • Embryos developed from the frozen-thawed oocytes.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
1,200 participants (estimated)

Study arms

  • Experimental
    Laser-assisted hatching system

    Embryos were exposed to a dose of laser energy focused outside the zona pellucida by aser-assisted hatching system.

    Device: Laser-assisted hatching system

  • No intervention
    Control group

    Nothing is done.

Interventions

  • DeviceLaser-assisted hatching system

    The ZP was thinned or drilled with the Laser-assisted hatching system. The laser pulse was 0.296 ms. Laser aperture was 8μm.

06

What researchers measure

Primary outcomes

  1. Efficacy of LAH in ART

    Assess the clinical pregnancy

    Time frame: 6 months

Secondary outcomes

  1. Feasibility of LAH in ART

    Incidence of LAH adverse events was assessed by miscarriage rate and multiple gestation rate.

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Tangdu Hospital
    Xi'an, Shaanxi 710038, China
    • Ming Wang · Contact
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03810157
Lead sponsor
Tang-Du Hospital
Responsible party
Sponsor
First posted
Jan 18, 2019
Start date
Dec 26, 2018
Primary completion
Oct 1, 2019 (estimated)
Completion
Nov 1, 2019 (estimated)
Last update
Jun 25, 2019

Study contacts

Ming Wang
Contact
wangmingbio@snnu.edu.cn
8613259809290
Bo Li
study chair · Tang-Du Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion